Silodosin

Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH[1][3].

Product Specifications

CAS Number

[160970-54-7]

Product Name Alternative

KAD 3213; KMD 3213

UNSPSC

12352005

Hazard Statement

H302, H373

Target

Adrenergic Receptor; Bacterial

Type

Reference compound

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Silodosin.html

Purity

99.82

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(N)C1=CC(C[C@@H](C)NCCOC2=CC=CC=C2OCC(F)(F)F)=CC3=C1N(CC3)CCCO

Molecular Formula

C25H32F3N3O4

Molecular Weight

495.53

Precautions

H302, H373

References & Citations

[1]Maxime Rossi , Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010; 4: 291–297.|[2]Villa L, et al. Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.Br J Pharmacol. 2013 May;169 (1) :230-8.|[3]Osman NI, et al.Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.Expert Opin Pharmacother. 2012 Oct;13 (14) :2085-96.|[4]Kawahara T, et al. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.Am J Cancer Res. 2015 Sep 15;5 (10) :2959-68. eCollection 2015.